TY - JOUR
T1 - Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes
AU - members of the Kidney Cancer group of the CCAFU
AU - Bigot, Pierre
AU - Bernhard, Jean Christophe
AU - Flamand, Vincent
AU - Gill, Inderbir
AU - Verhoest, Grégory
AU - Beauval, Jean Baptiste
AU - Nouhaud, François Xavier
AU - Suer, Evren
AU - Ploussard, Guillaume
AU - Hetet, Jean François
AU - Rigaud, Jérôme
AU - Baco, Eduard
AU - Larré, Stéphane
AU - Sebe, Philippe
AU - Koutlidis, Nicolas
AU - Descazeaud, Aurélien
AU - Eto, Masatoshi
AU - Doerfler, Arnaud
AU - Roupret, Morgan
AU - Vuong, Nam Son
AU - Reix, Boris
AU - Matsugasumi, Toru
AU - Bakri, Adnan El
AU - Albiges, Laurence
AU - Soulié, Michel
AU - Patard, Jean Jacques
AU - Méjean, Arnaud
AU - Bensalah, Karim
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Objective To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). Material and methods We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non–clear cell RCCs were analyzed. Results We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23–88) years. Median tumor size was 3 (1–11) cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. Conclusion Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.
AB - Objective To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC). Material and methods We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non–clear cell RCCs were analyzed. Results We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23–88) years. Median tumor size was 3 (1–11) cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively. Conclusion Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer.
KW - Chromophobe renal carcinoma
KW - Nephron-sparing surgery
KW - Oncologic outcomes
UR - http://www.scopus.com/inward/record.url?scp=85002822797&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2016.08.012
DO - 10.1016/j.urolonc.2016.08.012
M3 - Article
C2 - 27692834
AN - SCOPUS:85002822797
SN - 1078-1439
VL - 35
SP - 35.e15-35.e19
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 1
ER -